STOCK TITAN
  1. Home
  2. Sec-filings
  3. CAMP
  4. [Form 4] CAMP4 Therapeutics Corporation Insider Trading Activity

Camp4 Therapeutics Files Form 4 for 9,000-Share Option Grant to Director

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Camp4 Therapeutics Corp. (CAMP) filed a Form 4 detailing a routine director equity grant. On 06/25/2025, director Michael J. Higgins received a stock option covering 9,000 common shares at an exercise price of $1.56 per share. The option vests in full on the earlier of (i) the first anniversary of the grant date or (ii) the company’s next annual shareholders’ meeting, provided Mr. Higgins remains on the board. The option expires on 06/24/2035. Following the transaction, Mr. Higgins beneficially owns 9,000 derivative securities (options) and disclosed no additional direct or indirect common-stock holdings.
The filing was signed on 06/27/2025 by Josh Mandel-Brehm as Attorney-in-Fact.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Standard board option grant; no governance red flags or material investor impact.

This Form 4 documents a routine, board-service stock-option award to director Michael J. Higgins. The single grant of 9,000 options at $1.56 aligns with typical small-cap governance practices and includes a one-year or next-AGM vesting cliff, incentivising continued board participation without creating excessive dilution. No other equity movements or accelerated vesting provisions are disclosed, suggesting straightforward compliance with Section 16 reporting obligations.

TL;DR: Transaction is immaterial to valuation; neutral signal for CAMP shares.

The option grant represents a negligible fraction of CAMP’s outstanding share count and conveys no insight into operational performance or insider sentiment, as it is compensation-related rather than open-market buying. With no purchase of existing shares and no sale activity, the filing should have minimal trading impact. Investors may note the $1.56 strike as a reference point for management’s long-term value expectations, but overall, it neither strengthens nor weakens the investment thesis.

Insider Higgins Michael J
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 9,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 9,000 shares (Direct)
Footnotes (1)
  1. [object Object]
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Higgins Michael J
(Last) (First) (Middle)
C/O CAMP4 THERAPEUTICS CORPORATION
ONE KENDALL SQ., BLDG 1400 WEST, 3RD FL.
(Street)
CAMBRIDGE MA 02139
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Camp4 Therapeutics Corp [ CAMP ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $1.56 06/25/2025 A 9,000 (1) 06/24/2035 Common Stock 9,000 $0 9,000 D
Explanation of Responses:
1. The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the issuer's board of directors through the applicable vesting date.
Remarks:
/s/ Josh Mandel-Brehm, as Attorney-in-Fact 06/27/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did CAMP director Michael J. Higgins report on Form 4?

Grant of an option for 9,000 CAMP common shares at a $1.56 exercise price.

When do the 9,000 CAMP options granted to Michael J. Higgins vest?

They vest fully on the earlier of one year from 06/25/2025 or the next annual meeting.

What is the expiration date of the CAMP options issued to the director?

The options expire on 06/24/2035.

Did the Form 4 disclose any purchase or sale of CAMP common stock?

No. The filing shows only a derivative (option) grant; no common shares were bought or sold.

How many derivative securities does Michael J. Higgins own after the transaction?

He beneficially owns 9,000 stock options following the reported grant.